Jardiance 25 MG tablet 90S
Ended Awarded
- Contract number
- SPE2DB25FWCQV
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,661
Award facts
- Contract value 100% obligated
- $26,661.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $26,661.06 to AmerisourceBergen Drug Corp for 90-tablet units of Jardiance 25 mg tablets. The contract, executed on September 19, 2025, with an ultimate completion date of September 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order under its existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide.
The delivery order reflects AmerisourceBergen Drug Corp's critical role in federal medical procurement, particularly for military and veteran healthcare systems. Jardiance, a diabetes medication, represents the type of specialty pharmaceutical the company routinely supplies through its extensive federal contract portfolio. The company's competitively awarded contracts with DLA demonstrate its capability to meet federal procurement requirements across therapeutic domains including diabetes management, neurological treatments, pain management, and antibiotics. This transaction exemplifies the operational flexibility of the DLA's prime vendor global program structure, which enables efficient pharmaceutical distribution to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FWCQV?
SPE2DB25FWCQV was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 19, 2025.
How much is contract SPE2DB25FWCQV worth?
The government has obligated $26,661 on SPE2DB25FWCQV.
Is contract SPE2DB25FWCQV an order under another contract?
Yes. SPE2DB25FWCQV is a delivery order under SPE2DB25D3022, an indefinite delivery contract.
Was contract SPE2DB25FWCQV competed?
The extent of competition for SPE2DB25FWCQV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award